Fas ligand reduces viability in primary melanoma short-term cell cultures more than in metastatic melanoma short-term cell cultures

Dermatology

Volumn 211, Issue 4, 2005, Pages 318-324

  Hofbauer, Günther F L ^a   Hatta, Naohito ^a   Daigle, Isabelle ^c   Hemmi, Silvio ^b   Spanaus Schlapbach, Katharina ^a   Willers, Jörg ^a   Burg, Günter ^a   Simon, Hans Uwe ^c   Dummer, Reinhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c SWISS INSTITUTE OF ALLERGY AND ASTHMA RESEARCH SIAF   (Switzerland)

Author keywords

Apoptosis; Fas; Fas ligand; Melanoma; Tumor necrosis factor related apoptosis inducing ligand (TRAIL)

Indexed keywords

DNA FRAGMENT; FAS LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DISEASE SEVERITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROTEIN FUNCTION; SOLUBILITY;

ANTIGENS, CD95; ANTIGENS, SURFACE; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL SURVIVAL; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FAS LIGAND PROTEIN; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; JURKAT CELLS; LIGANDS; LYMPHATIC METASTASIS; MELANOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM STAGING; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; TUMOR NECROSIS FACTORS;

EID: 27844439069     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088500     Document Type: Article

References (16)

1. Wang J, Watanabe T: Expression and function of Fas during differentiation and activation of B cells. Int Rev Immunol 1999;18:367-379.
2. Ivanov VN, Bhoumik A, Ronai Z: Death receptors and melanoma resistance to apoptosis. Oncogene 2003;22:3152-3161.
3. Ferrarini M, Imro MA, Sciorati C, Heltai S, Protti MP, Pellicciari C, Rovere P, Manfredi AA, Rugarli C: Blockade of the Fas-triggered intracellular signaling pathway in human melanomas is circumvented by cytotoxic lymphocytes. Int J Cancer 1999;81:573-579.
4. Ekmekcioglu S, Okcu MF, Colome-Grimmer MI, Owen-Schaub L, Buzaid AC, Grimm EA: Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10. Melanoma Res 1999;9:261-272.
5. Ugurel S, Seiter S, Rappl G, Stark A, Tilgen W, Reinhold U: Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon-gamma. Int J Cancer 1999;82:727-736.
6. Shin MS, Park WS, Kim SY, Kim HS, Kang SJ, Song KY, Park JY, Dong SM, Pi JH, Oh RR, Lee JY, Yoo NJ, Lee SH: Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma. Am J Pathol 1999;154:1785-1791.
7. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J: Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape. Science 1996;274:1363-1366.
8. Owen-Schaub LB, van Golen KL, Hill LL, Price JE: Fas and Fas ligand interactions suppress melanoma lung metastasis. J Exp Med 1998;188:1717-1723.
9. Soubrane C, Mouawad R, Antoine EC, Verola O, Gil-Delgado M, Khayat D: A comparative study of Fas and Fas-ligand expression during melanoma progression. Br J Dermatol 2000;143:307-312.
10. Terheyden P, Siedel C, Merkel A, Kampgen E, Bröcker EB, Becker JC: Predominant expression of Fas (CD95) ligand in metastatic melanoma revealed by longitudinal analysis. J Invest Dermatol 1999;112:899-902.
11. Bullani RR, Wehrli P, Viard-Leveugle I, Rimoldi D, Cerottini JC, Saurat JH, Tschopp J, French LE: Frequent downregulation of Fas (CD95) expression and function in melanoma. Melanoma Res 2002;12:263-270.
12. Geertsen RC, Hofbauer GF, Yue FY, Manolio S, Burg G, Dummer R: Higher frequency of selective losses of HLA-A and -B allospecificities in metastasis than in primary melanoma lesions. J Invest Dermatol 1998;111:497-502.
13. Hofbauer GF, Schaefer C, Noppen C, Böni R, Kamarashev J, Nestle FO, Spagnoli GC, Dummer R: MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: Frequency and distribution. Am J Pathol 1997;151:1549-1553.
14. Chappell DB, Zaks TZ, Rosenberg SA, Restifo NP: Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res 1999;59:59-62.
15. Restifo NP: Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 2000;6:493-495.
16. Aragane Y, Maeda A, Cui CY, Tezuka T, Kaneda Y, Schwarz T: Inhibition of growth of melanoma cells by CD95 (Fas/APO-1) gene transfer in vivo. J Invest Dermatol 2000;115:1008-1014.